Clinical trial · Interventional
4D Phase Contrast MR: Hypertrophy in Liver Cancer
4D Phase Contrast MR: Validation and Evaluation of Hypertrophy in Liver Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient funding
Summary
Brief summary (as posted)
The investigators hypothesize that 4Dimensional Phase Contrast Magnetic Resonance Angiography (4D PC MRA) evaluation of portal venous flow predicts underlying liver function and hypertrophic potential in patients with liver cancer presenting for portal vein embolization (PVE). 4D PC MRA may provide a non-invasive measure of liver function that could help determine which patients could safely and successfully undergo PVE and subsequent resection of tumor. By comparing 4D PC MRA results with invasive catheter measurements the investigators will validate the flow findings. Further regression/correlation analysis with functional measures of the liver (HIDA scans), volumetrics, Doppler flow analysis, histology, and outcomes will help the investigators to determine the ability of 4D PC MRA to predict functional status and hypertrophic potential of the liver prior to PVE and hepatectomy allowing for better patient selection and reduced morbidity/mortality.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Liver | Malignant Liver Neoplasm | ALIAS | 0.90 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 4Dimensional Phase Contrast Magnetic Resonance Angiography | Device | — | UNRESOLVED |
| Portal vein embolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm 1: 4D phase contrast MR scan
- description
- * Each patient will undergo a total of 3 MRI/MRA scans (lasting 30-60 minutes): * Scan 1: Baseline (pre-portal vein embolization (PRE)) * Scan 2: Early after PVE (within 48 hours) * Scan 3: Late after PVE (at 3-8 weeks). * Scans 1 and 3: routine liver MR sequences with/without contrast (Gadoxetic acid, Eovist) and 4D phase contrast of the portal venous system. The 4D phase contrast sequence will be repeated twice at each time point, adding about 15-30 minutes to each scan. * Scan 2: 4D phase contrast sequences and imaging for localization.
- interventionNames
- Device: 4Dimensional Phase Contrast Magnetic Resonance Angiography
- Procedure: Portal vein embolization
Primary outcomes (5)
- measure
- Ability of the 4D PC MRA to measure portal venous flow findings compared to reference standards of catheter-based flow quantification
- timeFrame
- Up to 6-8 weeks post PVE
- description
- -Data from the 4D PC MRA will be compared with the reference standards of the catheter-based flow quantification to validate venous flow findings
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of malignant liver tumor * Clinically referred for portal vein embolization * At least 18 years of age * Willing and able to provide informed consent Exclusion Criteria: * Documented or reported contrast allergy * Unable to receive or tolerate MRI scan after evaluation of MRI screening form * GFR (glomerular filtration rate) \< 30 on labs drawn within 6 weeks of imaging.
References
Publications (0)
Data not yet available